TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24674873
Drug: Bosutinib at
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib at 400 mg/day plus exemestane at 25 mg/day
Study: 24674873
Drug: Bosutinib at
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib at 300 mg/day plus exemestane at 25 mg/day
Study: 24674874
Drug: Bosutinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib (400 mg/day) plus Letrozole (2.5 mg/day)
Study: 24676282
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers
Study: 24678902
Drug: Intravenous vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8 for 2 induction cycles.
Study: 24678902
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 on day 1 and oral vinorelbine 20 mg on days 1, 3 and 5 during concomitant radiotherapy 2 Gy daily, 5 days/week for a total of 66 Gy.
Study: 24682387
Drug: Impact of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of physician and empirical estimates of bleeding on treatment choice
Study: 24683529
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (EX) - resistance bands, 3 times weekly during chemotherapy
Study: 24684466
Drug: Teriparatide treatment
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide treatment for 18 months
Study: 24684785
Drug: Everolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (5 mg daily) and Carboplatin (AUC 6, later decreased to AUC 5 and AUC 4) every 3 weeks
Study: 24685375
Drug: Branched endograft
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched endograft treatment for arch aneurysms
Study: 24685375
Drug: Branched endograft
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched endograft treatment for arch aneurysms (early experience group)
Study: 24685605
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKA) in regular medical care
Study: 24685605
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKA) in telemedicine-based coagulation service
Study: 24685605
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKA) in both cohorts
Study: 24687156
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stents with biodegradable polymer
Study: 24687156
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stents with durable polymer
Study: 24687408
Drug: Low-dose gemcitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemcitabine (250 mg/m²) in a 6-h infusion plus cisplatin (35 mg/m²) on days 1 and 8 every three weeks
Study: 24687408
Drug: Low-dose gemcitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemcitabine infusion plus cisplatin
Study: 24688075
Drug: Standard-titer Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-titer Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age
Study: 24688075
Drug: Standard-titer Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age
Study: 24688075
Drug: Standard-titer Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age, with or without a second dose at 18 months of age
Study: 24691436
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (110 mg bid)
Study: 24692579
Drug: Trabectedin 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.3 mg/m(2) as a 3-h i.v. infusion every 3 weeks until progression or intolerance
Study: 24699474
Drug: ART (antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART (antiretroviral therapy)
Study: 24699910
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m² IV on days 1 and 8 of each 3-week cycle
Study: 24703206
Drug: Beta-blockers (carvedilol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses of 50mg, 200mg, and 10mg/day respectively.
Study: 24703206
Drug: Beta-blockers (carvedilol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses.
Study: 24704773
Drug: Asunaprevir 200
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir 200 mg twice daily in mild hepatic impairment
Study: 24704773
Drug: Asunaprevir 200
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir 200 mg twice daily in moderate hepatic impairment
Study: 24704773
Drug: Asunaprevir 200
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir 200 mg twice daily in severe hepatic impairment
Study: 24705186
Drug: Radotinib 400
Normalized name: Radotinib
DrugBank: Radotinib (DB12323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radotinib 400 mg twice daily for 12 cycles
Study: 24705975
Drug: Pazopanib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (400 or 600 mg daily)
Study: 24705975
Drug: Pazopanib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (600 mg) on Day 15 with bevacizumab (7.5 mg/kg iv)
Study: 24705975
Drug: Pazopanib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (600 mg) on Day 16 (24h after bevacizumab)
Study: 24707402
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (lansoprazole 30 mg twice daily, amoxicillin 0.75 g twice daily, clarithromycin 250 mg twice daily for 14 days)
Study: 24708624
Drug: HLA-A*2402-restricted multi-peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-A*2402-restricted multi-peptide vaccine combined with CRT (radiotherapy 60 Gy, cisplatin 40 mg/m², 5-fluorouracil 400 mg/m²)
Study: 24708667
Drug: Alpha fetoprotein
Normalized name: Alpha fetoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha fetoprotein DNA prime and adenovirus boost vaccination (3 plasmid DNA injections followed by 1 AdV injection, all intramuscularly)
Study: 24708726
Drug: Integrative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Medicine (IM) intervention at UAIHC
Study: 24710768
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy plus cetuximab (weekly cetuximab plus 3-week cycles of cisplatin/5-FU for up to 6 cycles)
Study: 24710768
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy plus cetuximab
Study: 24710915
Drug: Diet emphasizing
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet emphasizing dietary pulse intake (median dose of 130 g/d)
Study: 24711230
Drug: Progression risk
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progression risk score based on biological markers (CD38, ZAP-70, IGHV mutational status)
Study: 24711549
Drug: Lapatinib (7,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (7,000 mg per day in twice-daily dosing)
Study: 24711549
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of lapatinib
Study: 24711551
Drug: hu14.18K322A (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu14.18K322A (60 mg/m(2) per day for 4 days)
Study: 24714268
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors administration
Study: 24714750
Drug: Ombrabulin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (35 mg/m²) with docetaxel (75 mg/m²)
Study: 24714750
Drug: Ombrabulin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (30 mg/m²) with docetaxel (100 mg/m²)
Study: 24714750
Drug: Ombrabulin (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (42 mg/m²) with docetaxel (75 mg/m²)
Study: 24714750
Drug: Ombrabulin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (35 mg/m²) with docetaxel (100 mg/m²)
Study: 24714750
Drug: Ombrabulin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (30 mg/m²) with docetaxel (75 mg/m²)
Study: 24714750
Drug: Ombrabulin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (100 mg/m²) with docetaxel (100 mg/m²)
Study: 24714973
Drug: Zalutumumab (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalutumumab (weekly infusions, individually titrated to a grade 2 skin rash)
Study: 24715548
Drug: Pioglitazone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-30 mg/day) for 8 weeks
Study: 24716469
Drug: GSK933776 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK933776 1 mg/kg
Study: 24716469
Drug: GSK933776 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK933776 3 mg/kg
Study: 24716469
Drug: GSK933776 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK933776 6 mg/kg
Study: 24716542
Drug: Nab-paclitaxel (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (260 mg/m² i.v. on day 1 of each 21-day cycle)
Study: 24716655
Drug: Florbetapir F
Normalized name: Florbetapir F18
DrugBank: Florbetapir F-18 (DB09149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Florbetapir F 18 (amyloid imaging agent)
Study: 24717109
Drug: Ocaratuzumab 375
Normalized name: Ocaratuzumab
DrugBank: Ocaratuzumab (DB17359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocaratuzumab 375 mg/m(2) weekly for 4 weeks
Study: 24717362
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D (25(OH)D) ≥ ∼26 μg/L (65.0 pmol/L)
Study: 24717379
Drug: Lithium in
Normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium in monotherapy
Study: 24717379
Drug: Prophylactic medication
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic medication changed by psychiatrist
Study: 24717379
Drug: Prophylactic medication
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic medication stopped by patient
Study: 24717623
Drug: Lower respiratory
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower respiratory consultations with a course of antibiotics or oral steroids
Study: 24720900
Drug: Genetically modified
Normalized name: Genetically modified virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell treatment (gmDCs-CIK)
Study: 24721800
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol and atropine
Study: 24722222
Drug: Adults younger
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults younger than 55 years with severe burn injuries and inhalation injury
Study: 24723428
Drug: Active medical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medical therapy for GERD (n = 49)
Study: 24723493
Drug: Pentostatin, alemtuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentostatin, alemtuzumab, and low-dose high-frequency rituximab
Study: 24723677
Drug: Low-dose plerixafor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose plerixafor treatment
Study: 24725395
Drug: rHuIL-12 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL-12 at doses of 2, 5, 10, 12, and 15 μg; 20 μg in the FIH study; 12 μg in the phase 1b expansion study.
Study: 24726214
Drug: Atypical embryo
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical embryo phenotypes (AS, A1(cyt), AC, CC)
Study: 24726680
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg once daily for 7 days
Study: 24726680
Drug: HCTZ 25
Normalized name: HCTZ 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 25 mg once daily for 28 days
Study: 24726680
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg + HCTZ 25 mg once daily for 7 days
Study: 24732325
Drug: Low-dose non-adjuvanted
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose non-adjuvanted intradermal (ID) vaccine
Study: 24732325
Drug: Full-dose MF59-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose MF59-adjuvanted intramuscular (IM) vaccine
Study: 24732325
Drug: Full-dose MF59-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose MF59-adjuvanted IM vaccine
Study: 24732325
Drug: Low-dose non-adjuvanted
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose non-adjuvanted ID vaccine
Study: 24733245
Drug: Ibuprofen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (oral route, median dose of 10.0 mg/kg; range 3.4-11.4 mg/kg)
Study: 24733245
Drug: Ibuprofen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (oral route)
Study: 24733463
Drug: Posaconazole i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole i.v. 200 mg q.d.
Study: 24733463
Drug: Posaconazole i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole i.v. 300 mg q.d.
Study: 24733473
Drug: AVP-21D9 (anthrax
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP-21D9 (anthrax monoclonal antibody)
Study: 24733796
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg plus pertuzumab (840-mg loading dose, then 420 mg subsequently) every 3 weeks
Study: 24737778
Drug: Tivantinib 360
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib 360 mg b.i.d. with gemcitabine 1000 mg/m(2) weekly for 3 of 4 weeks
Study: 24737778
Drug: Tivantinib 360
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib 360 mg b.i.d. with gemcitabine
Study: 24738629
Drug: Idarubicin-loaded beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 5 mg
Study: 24738629
Drug: Idarubicin-loaded beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 10 mg
Study: 24738629
Drug: Idarubicin-loaded beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 15 mg
Study: 24738629
Drug: Idarubicin-loaded beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm)
Study: 24739978
Drug: Nonadjuvanted cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted cell culture-derived whole-virus H5N1 vaccine; two priming immunizations with clade 1 A/Vietnam H5N1 vaccine, booster with clade 2.1 A/Indonesia H5N1 vaccine 12 to 24 months later.
Study: 24739978
Drug: Safety and
Normalized name: HYDROCORTISONE ACETATE 10 mg in 1 g TOPICAL CREAM [American Safety and First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of the vaccine.
Study: 24741582
Drug: Rituximab monotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab monotherapy (4 weekly doses)
Study: 24741582
Drug: Rituximab monotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab monotherapy followed by CHOP-21 (16 out of 25 patients)
Study: 24742768
Drug: Tadalafil 40
Normalized name: tadalafil 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 40 mg/d
Study: 24743000
Drug: rAvPAL-PEG (0.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAvPAL-PEG (0.100 mg/kg)
Study: 24743391
Drug: Long-term parenteral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term parenteral nutrition (PN)
Study: 24746841
Drug: MABp1 (anti-interleukin-1α
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABp1 (anti-interleukin-1α monoclonal antibody) at 3.75 mg/kg every 2 weeks
Study: 24746841
Drug: MABp1 (anti-interleukin-1α
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABp1 (anti-interleukin-1α monoclonal antibody)
Study: 24747207
Drug: Demethylation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demethylation treatment with 5-aza-2'-deoxycytide
Study: 24747949
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² × 4 infusions) combined with three cycles of dexamethasone (28 mg/m², max. 40 mg) for 4 days at 2-week intervals
Study: 24748824
Drug: New disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: New disposable injection pen (GoQuick(®), Pfizer, Inc.)
Study: 24751453
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg weekly for 45 weeks
Study: 24752449
Drug: LY2523355 (litronesib)
Normalized name: Litronesib
DrugBank: Litronesib (DB11861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2523355 (litronesib) at 2 mg/m²/day
Study: 24752449
Drug: LY2523355 (litronesib)
Normalized name: Litronesib
DrugBank: Litronesib (DB11861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2523355 (litronesib) at 4 mg/m²/day
Study: 24752449
Drug: LY2523355 (litronesib)
Normalized name: Litronesib
DrugBank: Litronesib (DB11861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2523355 (litronesib) at 5 mg/m²/day
Study: 24753695
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (OCV) - 2 doses with a 2-week interval
Study: 24754273
Drug: IV abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV abatacept (10 mg/kg weight-tiered dosing) with MTX (up to 8 mg/week)
Study: 24754273
Drug: IV abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV abatacept (10 mg/kg weight-tiered dosing) monotherapy
Study: 24754273
Drug: IV abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV abatacept (10 mg/kg weight-tiered dosing) with and without background MTX
Study: 24755296
Drug: Capecitabine 750
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 750 mg/m2 twice a day during days 1-7, oxaliplatin 85 mg/m2 and bevacizumab 5 mg/kg on day 1, repeated every 14 days
Study: 24755296
Drug: Capecitabine, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine, oxaliplatin and bevacizumab combination
Study: 24755302
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular contrast injection with rotational C-arm CT (LV-RCT)
Study: 24755302
Drug: Aortic contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic contrast injection with rotational C-arm CT (Ao-RCT)
Study: 24758527
Drug: FOLFIRI® +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI® + bevacizumab (5 mg/kg bevacizumab, 180 mg/m2 irinotecan, 400 mg/m2 bolus FU, 400 mg/m2 leucovorin, followed by 46-hour FU infusions (2400 mg/m2))
Study: 24758722
Drug: Step-down treatment
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down treatment program (including short-term day hospital treatment followed by combined group and individual psychotherapy)
Study: 24758722
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Outpatient and Step-down)
Study: 24759933
Drug: Chewable tablets
Normalized name: Pepcix Chewable Tablets
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablets
Study: 24760402
Drug: Dexmecamylamine 8
Normalized name: Dexmecamylamine
DrugBank: Dexmecamylamine (DB11807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmecamylamine 8 mg (normal renal function and mild renal impairment)
Study: 24760402
Drug: TC-5412 2
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC-5412 2 mg (moderate renal impairment and ESRD)
Study: 24760402
Drug: Dexmecamylamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmecamylamine (single oral dose)
Study: 24761968
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and rituximab (3 induction cycles of weekly administration)
Study: 24763770
Drug: Telephone-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive-behavioral therapy for depression
Study: 24763965
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (n=186)
Study: 24763965
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy (n=95)
Study: 24764034
Drug: Steroid-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-based therapy (40 mg to 50 mg prednisone per day)